Brevan Howard Capital Management’s TG Therapeutics TGTX Stock Holding History

Brevan Howard Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Buy	25,281 +11,024	+77%	+$451K	0.01%	903
2026 Q1	$474K	Sell	14,257 -23,795	-63%	-$709K	﹤0.01%	1331
2025 Q4	$1.13M	Buy	38,052 +19,697	+107%	+$643K	0.01%	705
2025 Q3	$663K	Sell	18,355 -41,765	-69%	-$1.38M	﹤0.01%	1133
2025 Q2	$2.16M	Buy	60,120 +16,047	+36%	+$597K	0.01%	700
2025 Q1	$1.74M	Buy	44,073 +29,031	+193%	+$977K	0.02%	336
2024 Q4	$453K	Buy	+15,042	New	+$432K	﹤0.01%	652
2024 Q3	–	Sell	-53,190	Closed	-$946K	–	1432
2024 Q2	$946K	Buy	+53,190	New	+$849K	0.01%	397

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Brevan Howard Capital Management's TGTX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its TG Therapeutics (TGTX) stake by 77% in Q2 2026, buying an estimated $451K and bringing the position to 25,281 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #903.

Brevan Howard Capital Management first reported a position in TGTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.16M in Q2 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Brevan Howard Capital Management held 25,281 shares of TG Therapeutics worth $1.39M as of Q2 2026.
Brevan Howard Capital Management bought 11,024 TG Therapeutics shares in Q2 2026, an estimated $451K.
TG Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #903 holding.
Brevan Howard Capital Management first reported a position in TG Therapeutics in Q2 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's TG Therapeutics position peaked at $2.16M in Q2 2025.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.